U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Mon Mar 31 21:39:38 GMT 2025
Edited
by admin
on Mon Mar 31 21:39:38 GMT 2025
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
081I12ZA58
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTOCHROME P450 2C19
Common Name English
CYP2C19
Preferred Name English
HUMAN CYTOCHROME P450 2C19
Common Name English
CYTOCHROME P 450 2C19
Common Name English
Code System Code Type Description
UNIPROT
P33261
Created by admin on Mon Mar 31 21:39:39 GMT 2025 , Edited by admin on Mon Mar 31 21:39:39 GMT 2025
PRIMARY
CAS
391962-06-4
Created by admin on Mon Mar 31 21:39:39 GMT 2025 , Edited by admin on Mon Mar 31 21:39:39 GMT 2025
ALTERNATIVE
CAS
330589-90-7
Created by admin on Mon Mar 31 21:39:39 GMT 2025 , Edited by admin on Mon Mar 31 21:39:39 GMT 2025
PRIMARY
FDA UNII
081I12ZA58
Created by admin on Mon Mar 31 21:39:39 GMT 2025 , Edited by admin on Mon Mar 31 21:39:39 GMT 2025
PRIMARY
Related Record Type Details
Structure of TICLOPIDINE
SUBSTRATE -> METABOLIC ENZYME
Structure of FLUNITRAZEPAM
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of REGORAFENIB ANHYDROUS
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of TRIHYDROXYCHALCONE
SUBSTRATE -> METABOLIC ENZYME
Structure of Miridesap
NON-INHIBITOR -> METABOLIC ENZYME
Structure of Amitriptyline
SUBSTRATE -> METABOLIC ENZYME
Structure of SERATRODAST
SUBSTRATE -> METABOLIC ENZYME
Structure of NORTILIDINE
SUBSTRATE -> METABOLIC ENZYME
Structure of UAB-30
SUBSTRATE -> METABOLIC ENZYME
HUMAN LIVER
TISSUE EXPRESSION -> PARENT
Structure of CLOBAZAM
SUBSTRATE -> METABOLIC ENZYME
Structure of ENZALUTAMIDE
INHIBITOR -> METABOLIC ENZYME
Structure of TRAMADOL
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of BRANEBRUTINIB
INHIBITOR -> METABOLIC ENZYME
Structure of Oxcarbazepine
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of BIIB-021
SUBSTRATE -> METABOLIC ENZYME
Structure of PARATHION-METHYL
SUBSTRATE -> METABOLIC ENZYME
Structure of Diazepam
SUBSTRATE -> METABOLIC ENZYME
Structure of BOCIDELPAR
INHIBITOR -> METABOLIC ENZYME
Structure of VILAZODONE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of Lacosamide
SUBSTRATE -> METABOLIC ENZYME
Structure of Lurasidone
INHIBITOR -> METABOLIC ENZYME
MODERATE
Structure of ZIMLOVISERTIB
NON-INHIBITOR -> METABOLIC ENZYME
Structure of Rilpivirine
SUBSTRATE -> METABOLIC ENZYME
Structure of AMBRISENTAN
SUBSTRATE -> METABOLIC ENZYME
Structure of SOLIFENACIN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of SKF-8742
INHIBITOR -> METABOLIC ENZYME
Structure of ALDUMASTAT
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of Zanubrutinib
INDUCER -> METABOLIC ENZYME
Zanubrutinib is a weak inducer of CYP3A4 and CYP2C19 in vivo.
WEAK
Structure of BELZUTIFAN
SUBSTRATE -> METABOLIC ENZYME
Structure of UMBRALISIB
INHIBITOR -> METABOLIC ENZYME
Structure of ENCORAFENIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of FORMOTEROL
SUBSTRATE -> METABOLIC ENZYME
Structure of ANETHOLTRITHION
SUBSTRATE -> METABOLIC ENZYME
Structure of SELUMETINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of ELAGOLIX
INDUCER -> TARGET
Structure of ARTEMETHER
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of E-NORENDOXIFEN
INHIBITOR -> METABOLIC ENZYME
Structure of Berotralstat
INHIBITOR -> METABOLIC ENZYME
WEAK
Structure of LONAFARNIB
SUBSTRATE -> METABOLIC ENZYME
IN VITRO
Structure of PARATHION
SUBSTRATE -> METABOLIC ENZYME
Structure of MAVOGLURANT
SUBSTRATE -> METABOLIC ENZYME
Structure of Tofacitinib
NON-INHIBITOR -> METABOLIC ENZYME
Structure of LEMBOREXANT
INHIBITOR -> METABOLIC ENZYME
REVERSIBLE INHIBITION
IC50
Structure of ZOLPIDEM
SUBSTRATE -> METABOLIC ENZYME
Structure of TIMOLOL ANHYDROUS
SUBSTRATE -> METABOLIC ENZYME
Structure of MIDOMAFETAMINE
SUBSTRATE -> METABOLIC ENZYME
Structure of METHADONE
SUBSTRATE -> METABOLIC ENZYME
CYP2C19 preferentially metabolized (R)-methadone,
Structure of OTESECONAZOLE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of MDE
MDE
SUBSTRATE -> METABOLIC ENZYME
Structure of STIRIPENTOL
INHIBITOR -> METABOLIC ENZYME
Structure of Teriflunomide
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of ETHINYL ESTRADIOL
SUBSTRATE -> METABOLIC ENZYME
Structure of RUCAPARIB
INHIBITOR -> METABOLIC ENZYME
REVERSIBLE
Structure of IXAZOMIB
SUBSTRATE -> METABOLIC ENZYME
At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (< 1%).
Structure of PEXIDARTINIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of CHLORPYRIFOS
SUBSTRATE -> METABOLIC ENZYME
Structure of CENOBAMATE
SUBSTRATE -> METABOLIC ENZYME
Structure of IOFETAMINE
SUBSTRATE -> METABOLIC ENZYME
Structure of MOMELOTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of Zolunicant, (-)-
SUBSTRATE -> METABOLIC ENZYME
Structure of APREPITANT
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of DIPHENHYDRAMINE
SUBSTRATE -> METABOLIC ENZYME
CYP1A2, CYP2C9, and CYP2C19 are involved in the metabolism of diphenhydramine as low-affinity P450 isozymes.
Structure of RIFAMPIN
INDUCER -> METABOLIC ENZYME
POTENT
Structure of PROGUANIL
SUBSTRATE -> METABOLIC ENZYME
Structure of RITONAVIR
INDUCER -> METABOLIC ENZYME
POTENT
Structure of TECOVIRIMAT
INHIBITOR -> METABOLIC ENZYME
MINOR
Structure of NELFINAVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of SIMEPREVIR
INHIBITOR -> METABOLIC ENZYME
WEAK
IC50
Structure of 3-ISOXAZOLECARBOXAMIDE, N-(2,4-DICHLOROPHENYL)-5-METHYL-
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of VILAZODONE
INHIBITOR -> METABOLIC ENZYME
In vitro studies have shown that vilazodone is a moderate inhibitor of CYP2C19 and CYP2D6
Structure of SIMEPREVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of CANNABIDIOL
INHIBITOR -> METABOLIC ENZYME
Responsible for a drug interaction with clobazam. Mean increase in clozabam and N-desmethylclozabam levels was 60% and 500%, respectively, after 4 weeks of concomitant therapy.
Structure of PRETOMANID
INHIBITOR -> METABOLIC ENZYME
Pretomanid is a weak time-dependent inhibitor of CYP2C8 and CYP2C19.
TIME-DEPENDENT INHIBITION
Structure of Desloratadine
NON-INHIBITOR -> METABOLIC ENZYME
Structure of LICOFELONE
SUBSTRATE -> METABOLIC ENZYME
Structure of METHOXYCHLOR
SUBSTRATE -> METABOLIC ENZYME
Structure of ALVAMELINE
SUBSTRATE -> METABOLIC ENZYME
Structure of CAPSAICIN
SUBSTRATE -> METABOLIC ENZYME
Structure of LORLATINIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of Carbamazepine
INDUCER -> METABOLIC ENZYME
POTENT
Structure of FIDAXOMICIN
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of PHENYTOIN
INDUCER -> METABOLIC ENZYME
POTENT
Structure of Rifamycin
INHIBITOR -> METABOLIC ENZYME
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
Structure of CANNABIDIOL
SUBSTRATE -> METABOLIC ENZYME
Structure of MACITENTAN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of IDELALISIB
INHIBITOR -> METABOLIC ENZYME
IN VITRO
Structure of OSILODROSTAT
INHIBITOR -> METABOLIC ENZYME
TIME-DEPENDENT INHIBITION
Ki
Structure of BUPIVACAINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of FLUCONAZOLE
INHIBITOR -> METABOLIC ENZYME
Structure of LYS-006
NON-INHIBITOR -> METABOLIC ENZYME
IC50
Structure of FLUOXETINE
SUBSTRATE -> METABOLIC ENZYME
Structure of VORICONAZOLE
SUBSTRATE -> METABOLIC ENZYME
IN VITRO
Structure of ILAPRAZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of ETRASIMOD
SUBSTRATE -> METABOLIC ENZYME
MINOR
EXTENT PERCENTAGE
Structure of Suvorexant
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TRICLABENDAZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of Istisociclib
NON-INHIBITOR -> METABOLIC ENZYME
IC50
Structure of RHINACANTHIN C
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of NOMIFENSINE
SUBSTRATE -> METABOLIC ENZYME
Structure of Hexobarbital
SUBSTRATE -> METABOLIC ENZYME
Structure of ELAGOLIX
INHIBITOR -> TARGET
Ki
Structure of Apalutamide
INDUCER -> METABOLIC ENZYME
Structure of OMEPRAZOLE
INHIBITOR -> METABOLIC ENZYME
Structure of VELIPARIB
SUBSTRATE -> METABOLIC ENZYME
Structure of IMIPRAMINE
SUBSTRATE -> METABOLIC ENZYME
Structure of TRICLABENDAZOLE SULFONE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of Roflumilast
SUBSTRATE -> METABOLIC ENZYME
Structure of NE-100 FREE BASE
SUBSTRATE -> METABOLIC ENZYME
Structure of TASIMELTEON
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of ENASIDENIB
SUBSTRATE -> METABOLIC ENZYME
Structure of OSPEMIFENE
SUBSTRATE -> METABOLIC ENZYME
Ospemifene is primarily metabolized by CYP3A4, 2C9, and 2C19 responsible for approximately 40 to 50%, ~25%, and ~25%, respectively, of its clearance.
MAJOR
Structure of LOFEXIDINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of Gabapentin enacarbil
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of OLICERIDINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of CENOBAMATE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of MDMC
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of Binimetinib
SUBSTRATE -> METABOLIC ENZYME
Structure of ESCITALOPRAM
SUBSTRATE -> METABOLIC ENZYME
Structure of FLURBIPROFEN
INDUCER -> METABOLIC ENZYME
Structure of NORENDOXIFEN
INHIBITOR -> METABOLIC ENZYME
Structure of ATOMOXETINE
SUBSTRATE -> METABOLIC ENZYME
Structure of ENAVOGLIFLOZIN
SUBSTRATE -> METABOLIC ENZYME
Structure of OTESECONAZOLE
INDUCER -> METABOLIC ENZYME
mRNA levels in at least 2 hepatocyte cultures. Up 10 micromolar OTESECONAZOLE
Structure of TILIDINE
SUBSTRATE -> METABOLIC ENZYME
Structure of VORICONAZOLE
INHIBITOR -> METABOLIC ENZYME
Structure of REMIBRUTINIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of LOMITAPIDE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of FERROQUINE
SUBSTRATE -> METABOLIC ENZYME
Structure of PF-06835919
NON-INHIBITOR -> METABOLIC ENZYME
IC50
Structure of OSU-6162
SUBSTRATE -> METABOLIC ENZYME
Structure of LORCASERIN
SUBSTRATE -> METABOLIC ENZYME
Structure of Brivaracetam
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of PROPRANOLOL
SUBSTRATE -> METABOLIC ENZYME
Structure of TOPIRAMATE
INHIBITOR -> METABOLIC ENZYME
Structure of SKF-26754A
INHIBITOR -> METABOLIC ENZYME
Structure of TRICLABENDAZOLE SULFOXIDE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of MEPERIDINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of CLOZAPINE
SUBSTRATE -> METABOLIC ENZYME
Structure of CYCLOHEXANAMINE, N-(2-ETHOXYETHYL)-1-PHENYL-
SUBSTRATE -> METABOLIC ENZYME
Structure of U-48800
SUBSTRATE -> METABOLIC ENZYME
Structure of TICLOPIDINE
INHIBITOR -> METABOLIC ENZYME
Structure of VERUBECESTAT
NON-INHIBITOR -> METABOLIC ENZYME
Structure of PROADIFEN
INHIBITOR -> METABOLIC ENZYME
SELECTIVE
Structure of GS-563117
INHIBITOR -> METABOLIC ENZYME
Structure of COBICISTAT
NON-INHIBITOR -> METABOLIC ENZYME
Structure of CHLORAMPHENICOL
INHIBITOR -> METABOLIC ENZYME
MIXED INHIBITION
MAJOR
Ki
Structure of PANOBINOSTAT
INHIBITOR -> METABOLIC ENZYME
Structure of BMS-823778 FREE BASE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of MICONAZOLE
INHIBITOR -> METABOLIC ENZYME
Structure of CYCLOHEXANAMINE, N-(3-ETHOXYPROPYL)-1-PHENYL-
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of DIETHYLTOLUAMIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of APIXABAN
NON-INHIBITOR -> METABOLIC ENZYME
Structure of PANTOPRAZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of OSPEMIFENE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of OXYMETAZOLINE
SUBSTRATE -> METABOLIC ENZYME
Structure of .ALPHA.-PYRROLIDINOPENTIOPHENONE
SUBSTRATE -> METABOLIC ENZYME
Structure of 2,4-DICHLOROANILINE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of OMEPRAZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of Isavuconazole
INHIBITOR -> METABOLIC ENZYME
Structure of LESINURAD
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of CYCLOPHOSPHAMIDE ANHYDROUS
SUBSTRATE -> METABOLIC ENZYME
Structure of PANOBINOSTAT
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of RAMELTEON
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of MECLIZINE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of ALVESPIMYCIN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of 1-(((4-((7-METHOXY-6-(SULFOOXY)-4-QUINOLINYL)OXY)PHENYL)AMINO)CARBONYL)CYCLOPROPANECARBOXYLIC ACID
SUBSTRATE -> METABOLIC ENZYME
Structure of PF-05212377
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of 5-[(2,4-Dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide
SUBSTRATE -> METABOLIC ENZYME
Structure of SEBETRALSTAT
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of FLUVOXAMINE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of RABEPRAZOLE SODIUM
SUBSTRATE -> METABOLIC ENZYME
Structure of FEDRATINIB
SUBSTRATE -> METABOLIC ENZYME
Metabolized by CYP3A4 (0 to 70%), CYP2C19 (0?20%), and FMO3 (0?33%) in vitro.
Structure of SELICICLIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of MEPHENYTOIN, (+)-
SUBSTRATE -> METABOLIC ENZYME
Structure of 4'-METHYL-.ALPHA.-PYRROLIDINOBUTIOPHENONE
SUBSTRATE -> METABOLIC ENZYME
Structure of VALDECOXIB
SUBSTRATE -> METABOLIC ENZYME
Structure of Belumosudil
INHIBITOR -> METABOLIC ENZYME
Inhibits at clinically relevant concentrations.
Structure of DRONABINOL
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of N-(2-METHOXYETHYL)-1-PHENYLCYCLOHEXANAMINE
SUBSTRATE -> METABOLIC ENZYME
Structure of FLUOXETINE
INHIBITOR -> METABOLIC ENZYME
Moderate inhibitor
Structure of Tofacitinib
SUBSTRATE -> METABOLIC ENZYME
Structure of VOXELOTOR
SUBSTRATE -> METABOLIC ENZYME
In vitro metabolism studies involving recombinant enzymes indicated that CYP3A4, CYP1A1, CYP3A5, CYP2C9, CYP2C19 and CYP2B6 were responsible for the oxidative metabolism of voxelotor.
Structure of PHENYTOIN
SUBSTRATE -> METABOLIC ENZYME
Structure of ENZALUTAMIDE
INDUCER -> METABOLIC ENZYME
Therefore, co-administration of enzalutamide with CYP3A4, 2C9, and 2C19 substrates with a narrow therapeutic index should be avoided.
MODERATE
Structure of N-(3-METHOXYPROPYL)-1-PHENYLCYCLOHEXANAMINE
SUBSTRATE -> METABOLIC ENZYME
Structure of LUSUTROMBOPAG
INHIBITOR -> TARGET
MINOR
Structure of LANSOPRAZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of SELEGILINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ETRAVIRINE
SUBSTRATE -> METABOLIC ENZYME
Structure of LONAFARNIB
INHIBITOR -> METABOLIC ENZYME
Structure of DIMPYLATE
SUBSTRATE -> METABOLIC ENZYME
Structure of RIVOGLITAZONE
SUBSTRATE -> METABOLIC ENZYME
Structure of ETORICOXIB
SUBSTRATE -> METABOLIC ENZYME
Structure of ABROCITINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of DELAVIRDINE
INDUCER -> METABOLIC ENZYME
Structure of Bortezomib
SUBSTRATE -> METABOLIC ENZYME
Structure of GILTERITINIB
INHIBITOR -> METABOLIC ENZYME
WEAK
IC50
Structure of WARFARIN, (R)-
SUBSTRATE -> METABOLIC ENZYME
Structure of Desloratadine
SUBSTRATE -> METABOLIC ENZYME
Structure of ISONIAZID
INHIBITOR -> METABOLIC ENZYME
POTENT

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
Heme binding [1_435] CYS HEME-CYSTEINE (OXIDIZED) G0HAF1JK3T
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966